News | November 10, 2023
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Total transaction value of the divestment is Rs. 3,660 million
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Max Healthcare Institute has reported total income of Rs. 1408.64 crores during the period ended September 30, 2023
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
Zydus Wellness has reported total income of Rs. 444 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
